High-yield map
Key points before the detail
- 01
Neoplasia is clonal, autonomous relative to normal controls and driven by accumulated molecular change.
- 02
Dysplasia is pre-invasive epithelial atypia/disordered maturation; invasion is a separate biological step.
- 03
Carcinomas are malignant epithelial tumours; sarcomas are malignant mesenchymal tumours.
- 04
The “-oma means benign” rule has important exceptions, so classify by tissue and biology rather than suffix alone.
What makes a proliferation neoplastic?
Reactive hyperplasia and metaplasia occur in response to physiological or pathological signals and remain linked to those stimuli. Neoplastic cells acquire changes that give a clone a selective growth advantage and increasingly autonomous behaviour. Tumours continue to evolve, so different subclones may coexist within the same lesion.
Dysplasia, carcinoma in situ and invasion
| Term | Meaning |
|---|---|
| Dysplasia | Disordered epithelial maturation and cytological/architectural atypia; severity is graded using organ-specific systems. |
| Carcinoma in situ | Full-thickness/high-grade pre-invasive epithelial neoplasia in an organ where this term is applicable, with basement-membrane integrity maintained. |
| Invasive carcinoma | Malignant epithelial cells breach the normal epithelial boundary/basement-membrane compartment and invade supporting tissue. |
Classify by tissue of origin
| Lineage | Typical malignant term |
|---|---|
| Epithelial | Carcinoma |
| Mesenchymal/connective tissue | Sarcoma |
| Haematolymphoid | Leukaemia / lymphoma and related entities |
| Melanocytic | Melanoma when malignant |
| Germ-cell and embryonal | Uses organ- and lineage-specific terminology |
Benign versus malignant behaviour
| Feature | Benign tendency | Malignant tendency |
|---|---|---|
| Differentiation | Often resembles tissue of origin | May range from well differentiated to anaplastic |
| Growth | Usually slower and expansile | Often faster and infiltrative, but rate varies greatly |
| Local invasion | Absent | Present by definition for invasive malignancy |
| Metastasis | Absent | Possible; strongly supports malignancy when present |
Modern classification adds molecular information
Morphology remains fundamental, but many contemporary tumour classifications incorporate immunohistochemistry, defined molecular alterations or genomic signatures because these improve diagnostic precision, prognosis or treatment selection. The correct level of detail is organ-specific and changes as classifications are updated.
Active recall
Close the notes and answer these
Try each question from memory before revealing the answer. These public prompts are a small preview of the integrated retrieval system inside SurgAtlas.
01What is the essential difference between carcinoma in situ and invasive carcinoma?
In invasive carcinoma, malignant epithelial cells have breached the normal epithelial boundary and invaded supporting tissue; carcinoma in situ remains pre-invasive.
02What is a sarcoma?
A malignant tumour of mesenchymal/connective-tissue lineage.
03Why is the suffix “-oma” unreliable for deciding benign versus malignant?
There are important malignant exceptions such as melanoma and lymphoma, so behaviour and histogenesis matter more than the suffix.
Sources & editorial basis
References & editorial basis
- SurgAtlas production chapter — Neoplasia — Definitions and Classification. Primary source for this public lesson. The public teaching is a condensed, source-derived version of the corresponding production pathology chapter.
- WHO Classification of Tumours. Organ-specific classifications increasingly integrate morphology, immunophenotype and molecular findings; exact criteria depend on tumour site and current edition.
This lesson is derived from the corresponding SurgAtlas production teaching material. Where the source makes current management or guideline claims, the public lesson uses the cited contemporary guidance. It is written for education and examination preparation, not as patient-specific clinical advice.
Editorial details
Medical Doctor (MD) · MRCS Part A · Physician · Surgical Educator
SurgAtlas is an educational resource. For patient care, verify current national guidance, local antimicrobial and transfusion policies, specialty pathways and individual patient factors.
Continue in SurgAtlas
Turn reading into retrieval.
Use the full learning workspace for chapter progress, integrated questions, review scheduling and exam-focused study tools. Free accounts do not include recurring AI usage.